Cystic disease of the kidney
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
  • very nice.Thank you very much
    Are you sure you want to
    Your message goes here
  • Hi can you let me know where you got this image from?
    Thanks
    Aneesha
    Are you sure you want to
    Your message goes here
No Downloads

Views

Total Views
7,689
On Slideshare
6,583
From Embeds
1,106
Number of Embeds
14

Actions

Shares
Downloads
312
Comments
2
Likes
3

Embeds 1,106

http://www.nephronpower.com 507
http://doctorrw.blogspot.com 337
http://www.webicina.com 244
http://doctorrw.blogspot.in 7
http://doctorrw.blogspot.ca 2
http://doctorrw.blogspot.com.br 1
http://doctorrw.blogspot.ch 1
http://translate.googleusercontent.com 1
http://doctorrw.blogspot.nl 1
http://doctorrw.blogspot.com.au 1
http://doctorrw.blogspot.co.uk 1
http://doctorrw.blogspot.com.es 1
http://doctorrw.blogspot.co.il 1
http://doctorrw.blogspot.hk 1

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1.  
  • 2.
    • Definition
    • Pathophysiology
    • Classification (or lack thereof)
    • Diseases
  • 3.
    • Cyst: fluid-filled sac that grows on the surface of, or within the kidney
    • Generally arise from renal tubules
  • 4.  
  • 5.  
  • 6.
    • No good classification system – 9 proposed schema over past 120 years
    • Classification initially began with structural features, but has evolved to include advances in genetics
    • Ideal scheme would take into account morphological features, pathogenesis, and therapeutic potential
  • 7.  
  • 8.
    • Genetic vs Non-genetic
    • Congenital vs Acquired
    • Isolated vs Systemic Disease
    • Malignant Potential
  • 9.  
  • 10. Disease Kidney Size Cyst Size Cyst Location Liver Nephronophthisis Small 1MM-2CM Medullary Normal Acquired Cysts Normal/Small 0.5-3CM Any Normal Medullary Sponge Normal/Enlarged MM Precalyceal Normal ARPKD Enlarged MM Any Fibrosis Multicystic Dysplastic Enlarged 1MM-10CM Any Normal ADPKD Enlarged MM-10CM Any Cysts
  • 11.
    • Prevalence 1:400 to 1:1000, but estimated ½ cases clinically silent and undiagnosed
    • Commonest defect is in PKD1 gene on chromosome 16 (85-95%), or PKD2 on chromosome 4
    • Cysts/ESRD occur later in PKD2 vs PKD1 (mean age of ESRD is 74 vs 54)
  • 12.
    • PKD1/2 encode genes for Polycystin 1/2
    • Polycystin1 involved in cell-cell interactions; activates JAK-STAT pathway, causing cell cycle arrest
    • Polycystin2 involves calcium signaling via G-proteins
    • Expressed in renal tubulular epithelium, hepatic bile ducts, and pancreatic ducts
  • 13.  
  • 14.  
  • 15. Diagnosis/Screening
    • Diagnosis generally relies on imaging (usually U/S); sometimes genetic testing is required for definitive diagnosis
    • 3 main criteria: family history, number/type of cysts, age of patient
    • Screening not recommended before age 18 (psychological)
  • 16. Family History Positive - Genotype Unknown
    • Age 15-39: 3 or more unilateral or bilateral cysts (sensitivity 82-96%, specificity 100%)
    • Age 40-59: 2 or more cysts in each kidney (sensitivity 90%, specificity 100%)
    • Age 60 or more: 4 or more cysts in each kidney (sensitivity/specificity 100%)
  • 17. Family History of PKD1
    • Genetic screening is often better
    • Age 15-30: At least two unilateral or bilateral cysts (sens 95%, spec 100%)
    • Age 30-59: At least 2 cysts in each kidney (sensitivity 97%, specificity 100%)
    • Age >60: 4 cysts in each kidney (sensitivity 97%, specificity 100%)
  • 18. Family History of PKD2
    • Genetic testing recommended
    • Same ultrasound criteria as unknown genotype
  • 19. Criteria for Exclusion of Disease (if family history positive)
    • Age <30: no criteria
    • Age 30-39: No cysts – false negative rate of 2%
    • Age >40: 0 or 1 cyst (NPV 100%)
  • 20. Alternate Imaging
    • CT and MRI are more sensitive and may pick up smaller cysts
    • No studies have examined diagnostic criteria with these modalities
    • Current opinion – if no cysts detected in kidney or liver by age 20, may exclude disease; if results inconclusive, genetic testing should be pursued
  • 21. Absence of Family History
    • What about patients who meet criteria but have no family history of disease?
    • 25% of these patients have an undiagnosed relative (can screen family); 5% represent new mutation
    • In absence of FH, there is no definitive criteria – diagnosis suspected if >10 cysts in each kidney; other cystic disease should be considered
  • 22. Genetic Testing
    • Linkage analysis: uses microsatellite DNA markers that flank the PKD genes
    • Requires at least 4 diagnosed family members; therefore useful in <1/2 of cases
  • 23. Direct DNA Analysis
    • Difficulty arises from large size of gene, multitude of “PKD-like” genes, and heterogeneity of alleles
    • 65-70% detection rates with liquid chromatography
    • 85-90% detection with direct sequencing
    • Drawback: mutation of gene does not necessarily lead to pathology
  • 24. Clinical Course
    • Symptoms may present as flank pain, hematuria, proteinuria, calculus, UTI, HTN, renal insufficiency
    • Renal function intact until 4 th decade, and declines at rate of 4-6ml/min per year (faster with PKD1, proteinuria, HTN, male)
  • 25.
    • Cerebral Aneurysm
    • 4-10% based on age; family history of aneurysm or SAH increases risk
    • Rupture occurs with larger aneurysms and with poorly controlled HTN
    • SAH presents as acute severe headache
    • CT scan might miss small bleed – lumbar puncture should be done 6-12 hrs later
  • 26.  
  • 27.
    • Role of radiological screening studies in asymptomatic patients with ADPKD is controversial
    • Rate of interventional-related morbidity/mortality is 13.7%
    • Routine screening recommended for high-risk pts (previous rupture, FH, high-risk occupation)
  • 28.
    • Procedures of choice are CTA/MRA (but beware NSF with GFR<30 {?<60})
    • Suggested screening is yearly for 3 years, and if stable, every 2-5 years afterwards
    • Unknown if warfarin increases risk of bleeding; reasonable to screen these pts
  • 29.
    • Hepatic Cysts
    • Prevalence of ~80% in pts age 15-45
    • Massive cysts occur almost exclusively in women; multiple pregnancies accelerates growth (? Estrogen)
    • Most asymptomatic; some require pain control or antibiotics
  • 30.  
  • 31.
    • Cardiac Disease
    • Valvular abnormalities in 30% (MVP, AR)
    • Coronary aneurysms not infrequent
    • Asymptomatic pericardial effusion seen in 35%, with 50% of these being moderate to severe in size
  • 32.
    • Other
    • Colonic Diverticula (abd pain may be misleading)
    • Abd wall hernia in up to 45% (consideration in PD patients)
  • 33.
    • No treatment has been proven to delay progression of disease
    • Control of HTN should be attained with ACE-I (increased RAS activity from focal ischemia due to cyst expansion)
    • Nephrectomy is sometimes necessary for transplant, recurrent UTI, RCC, chronic pain, chronic hematuria
  • 34.
    • Ideas for the future?
    • MTOR inhibitors: show some benefit in limiting the increase in kidney size, but do not limit the decrease in GFR (over 2 yrs) and cause more proteinuria
    • Vasopressin receptor antagonists have shown promising results in mice/rat models (via intracellular cAMP), phase 3 trials in progress
  • 35.  
  • 36.  
  • 37. ARPKD
    • Estimated incidence 1:10,000-40,000
    • Generally diagnosed in pediatric age; cases diagnosed in adulthood have mild renal impairment but more hepatic dysfunction
    • PKHD1 gene encodes fibrocystin, a cilial protein of cortical/medullary collecting ducts and hepatic bile duct
  • 38. Features
    • Kidneys enlarge due to microcysts (<3mm)
    • Liver always has hepatic fibrosis (portal hypertension, ascites, esophageal varices)
    • Diagnostic criteria: imaging criteria plus one of following: absence of cysts in parents, sibling with disease, evidence of hepatic fibrosis
  • 39.  
  • 40. Nephronophthisis
    • Autosomal recessive, heterogenous disorder affecting proteins in cilia
    • Characteristic findings: reduced urinary concentrating ability; chronic tubulointerstitial nephritis resulting in ESRD by age of 20
    • Commonest extrarenal manifestation is retinitis pigmentosa (20%)
  • 41. Manifestations
    • Presents as polyuria/polydipsia due to impaired concentration of urine
    • Hepatic Fibrosis
    • Situs Inversus
  • 42. Diagnosis
    • -Polyuria with bland urinalysis
    • -Progressive CKD without HTN
    • -Normal Size Kidneys
    • If above 3 are present, genetic testing should be undertaken
    • If genetic test negative, biopsy can be suggestive – tubulointerstitial nephritis with thickened basement membrane
  • 43.
    • Medullary cysts in normal-sized kidneys
  • 44. Medullary Cystic Kidney Disease
    • A rare (~50 cases per year in USA) autosomal dominant disease
    • Two types, with variable clinical courses - ESRD at age 20-70
  • 45. MCKD2
    • Also called Familial Juvenile Hyperuricemia
    • Describes families with mutations in the uromodulin gene – a Tamm-Horsfall mucoprotein
  • 46.
    • Uromodulin is produced exclusively in thick ascending limb of Loop of Henle
    • It is a sticky insoluble protein which may assist with water-tight integrity
    • Mutant proteins cannot exit cell, and cause tubular atrophy/death
  • 47.
    • Hyperuricemia/Gout results from reduced urate excretion (mechanism not well understood)
    • Progressive decline in renal function secondary to tubular death
  • 48.
    • 3 criteria:
    • -Family history of renal disease in autosomal dominant pattern
    • -Family History of Gout
    • -Bland Urinary sediment without little or no proteinuria
    • Definitive Diagnosis through genetic test, which is cheaper and more specific than biopsy (IF with antibody to uromodulin shows deposition in tubules)
  • 49.
    • Gout is best controlled with allopurinol; uncertain whether this slows progression of kidney disease
  • 50. MCKD1
    • Gene within chromosome 1q21 has not been identified, so pathophysiology unknown
    • HTN and Hyperuricemia are more prevalent as renal function declines, therefore late features (contrast to MCKD2)
    • Course within families in extremely variable (ESRD ranging from age 30-75)
  • 51.
    • Biopsy reveals tubular atrophy, interstitial fibrosis, splitting of basement membrane (which is thick and irregular)
    • No specific treatment
    • Transplant is preferred therapy – disease will not recur
  • 52.
    • A congenital dysplasia in which a mass of cysts and connective tissue forms, with no identifiable renal tissue
    • Usually unilateral, with compensatory hypertrophy of remaining kidney (but may have positional or structural defect)
    • Often detected on prenatal sonography, or palpable flank mass
  • 53.  
  • 54.
    • Evaluation of contralateral kidney, including ultrasound and voiding cytourethrography to rule out vesicoureteral reflux (25%)
    • No indication for nephrectomy (no increased risk of Wilms tumor)
  • 55.
    • Characterized by malformation of terminal collecting ducts in pericalyceal region of pyramids
    • Generally clinically benign, but recurrent nephrolithiasis and UTI may lead to renal insufficiency
    • Sometimes autosomal dominant, but usually sporadic mutations
  • 56.
    • Prevalence unknown, but seen in 10-20% of patients who form calcium stones
    • Diagnosis usually incidental - made by IVP, with dilation of cystic ducts showing “brush” appearance radiating outward from calyces
    • U/S and CT less specific – show nephrocalcinosis
  • 57.  
  • 58.  
  • 59.
    • Usually asymptomatic - incidental
    • Recurrent calcium phosphate or calcium oxalate stones – concretions within cysts act as nidus for stone formation
    • UTI (secondary to stones, stasis)
    • Hematuria
  • 60.
    • Patients with stone risk factors (hypercalciuria, hyperuricosuria, hyperoxaluria, hypocitraturia) may benefit from potassium citrate
    • Initial dose 20meq/day titrated to urinary citrate level of 450mg/day
  • 61.
    • Tuberous Sclerosis
    • Autosomal dominant; 1/3 familial
    • Characterized by formation of angiomyolipomas of skin, brain, kidneys, other organs
    • 2 genes – TSC1 (hamartin) and TSC2 (tuberin)
  • 62.  
  • 63.
    • Commonest lesion is angiomyolipoma (50-70%), then benign cysts (30-50%)
    • Symptoms include flank pain, hematuria from mass effect of angiomyolipoma; cysts usually asymptomatic
    • Renin-dependent HTN from ischemia
    • Since TSC2 gene is adjacent to PKD1, some have both diseases
  • 64.
    • ESRD can occur from mass effect
    • RCC in 1-2% - U/S every 1-3 years
    • Intervention for pain, bleeding, malignancy – 1 st line is arterial embolization, second line is partial or total nephrectomy
  • 65. Treatment
    • Since angiomyolipoma is associated with phosphorylation by MTOR, there is limited evidence that rapamycin decreases size of mass by 50%, but returns upon discontinuation of drug
    • Transplantation should be accompanied by bilateral nephrectomy due to increased risk of RCC by immunosuppresssion
  • 66. Von-Hippel Lindau
    • Autosomal dominant syndrome with a variety of benign and malignant tumors
    • Commonest systemic lesion is hemangioblastoma of eye/brain; pheochromocytoma in 10-20%
    • Renal involvement includes multiple cysts and RCC (2/3 of pts)
  • 67.
    • RCC often multicentric and bilateral, therefore cysts are benign, but considered premalignant
    • Screening for RCC should begin in adolescence
    • No guidelines, but current opinion is annual ultrasound, plasma catecholamine, retinal exam, MRI brain and spine with gad at age 10
  • 68.
    • New tumors arise every 5 years in 30% of pts; every 10 years in 85%
    • Small lesions may be observed (<3cm), or undergo radiation ablation, cryotherapy, or partial nephrectomy
    • Transplantation feasible in setting of bilateral nephrectomy; minimal data available regarding RCC recurrence
  • 69.
    • HD and PD associated with development of multiple bilateral small cysts; usually less than 0.5cm but up to 3 cm
    • Criteria: 4 or more total cysts in both kidneys
    • Differentiated from ADPKD by lack of family history, small/normal size kidneys, smooth contoured kidneys
  • 70.
    • Incidence increases with increased time on dialysis; also occurs in children
    • Pathogenesis unknown; believed to be result of compensatory hypertrophy leading to tubular hyperplasia and cysts
    • Cysts may regress following transplant
  • 71.
    • Commonest symptoms: hematuria, lumbar pain, UTI
    • RCC has varied incidence, ~5%; malignancy develops after 8-10 years on dialysis; risk factors are male and large cysts
    • No guidelines for screening; some suggest radiological studies only for new symptoms (hematuria/flank pain), or young pts (long duration of HD)
  • 72.
    • The term is histopathological (descriptive); Can only be distinguished from tubular cystic disease by biopsy
    • A rare disease that may be seen independently; but more commonly in association with other pathology
    • Often a pediatric diagnosis
  • 73.  
  • 74. Classifications of glomerulocystic kidney disease Example Familial nonsyndromic Autosomal dominant polycystic kidney disease in young infants Associated with inheritable malformation syndromes Tuberous sclerosis complex Syndromic, non-Mendelian Trisomy 9, 13, or 18 Sporadic New mutations Acquired and dysplastic kidneys Hemolytic uremic syndrome and obstructive uropathy